LIXT - Lixte Biotechnology Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue-200-
Cost of Revenue---
Gross Profit-200-
Operating Expenses
Research Development1,301.1332,091.9731,117.97
Selling General and Administrative833.782754.441,285.173
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-2,134.915-2,646.413-2,403.143
Income from Continuing Operations
Total Other Income/Expenses Net0.183-205.695-363.045
Earnings Before Interest and Taxes-2,134.732-2,852.108-2,766.188
Interest Expense---
Income Before Tax-2,134.732-2,852.108-2,766.188
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-2,134.732-2,852.108-2,766.188
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-2,134.732-2,852.108-2,766.188
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-2,134.732-2,854.108-2,766.188